Suberoylanilide Hydroxamic Acid in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

NCT00138203 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

16

Enrollment

NIH

Sponsor class

Conditions

Recurrent Non-small Cell Lung Cancer
Stage IIIB Non-small Cell Lung Cancer
Stage IV Non-small Cell Lung Cancer

Interventions

DRUG: vorinostat
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)